Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990)
Hong Kong
· Delayed Price · Currency is HKD 412.80
+32.80 (8.63%)
Last updated: Mar 10, 2026, 1:37 PM HKT
HKG:6990 Revenue
Sichuan Kelun-Biotech Biopharmaceutical had revenue of 950.45M CNY in the half year ending June 30, 2025, a decrease of -9.15%. This brings the company's revenue in the last twelve months to 1.50B, down -20.05% year-over-year. In the year 2024, Sichuan Kelun-Biotech Biopharmaceutical had annual revenue of 1.93B with 25.48% growth.
Revenue (ttm)
1.50B CNY
Revenue Growth
-20.05%
P/S Ratio
53.89
Revenue / Employee
802.51K CNY
Employees
1,870
Market Cap
88.61B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.93B | 392.55M | 25.48% |
| Dec 31, 2023 | 1.54B | 736.56M | 91.62% |
| Dec 31, 2022 | 803.93M | 771.61M | 2,387.26% |
| Dec 31, 2021 | 32.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSichuan Kelun-Biotech Biopharmaceutical News
- 3 months ago - Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up - Nasdaq